Carl Zeiss Meditec AG
At the ESCRS, the congress of the European Society of Cataract and Refractive Surgeons, Carl Zeiss Meditec presents new products and highlights for ophthalmology
JENA, 15 September 2011
In Vienna Carl Zeiss Meditec is presenting its expanded offering of solutions for cataract and refractive surgery. The booth on which the new products will be exhibited integrates the company's New Brand Communication initiative. “The moment innovation and passion lead to the best vision for your patient. This is the moment we work for,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. He continues: “This moment describes our aspiration to make our contribution to medical progress in ophthalmology with our products and solutions and create added value for doctors in their daily work."
The breadth of our product offering allows the implementation of simple, uninterrupted workflows. These generate efficiency in treatment through optimally synchronized system components and support the clinical work.
With FORUM Carl Zeiss offers a solution that, through comprehensive image and data management, simplifies workflows in the ophthalmologist's office and combines and centrally stores data from several diagnostic systems. FORUM LINK Tools from Carl Zeiss additionally allow the smooth integration of systems from other manufacturers that do not support the DICOM standard or do not feature a network interface.
A further focus point of the exhibits will be the ZEISS MICS Platform, the market’s widest range of MICS intraocular lenses (IOLs), ophthalmic viscoelastic devices (OVDs) and VISALIS phaco technology for microincision surgery. A new product is the BLUEMIXS 180 Injector that can be used for the implantation of preloaded refractive ZEISS MICS intraocular lenses (multifocal, toric and multifocal toric IOLs). The lenses do not need to be loaded first and therefore ensure fast, safe implantation. The injector allows an incision of 1.8 mm and is therefore MICS-compatible.
To supplement the MICS platform, Carl Zeiss is offering a comprehensive solution for cataract diagnosis and surgery. Here, the implantation of toric IOLs is also supported in particular (ZEISS Toric Solution). This solution is supplemented with the OPMI LUMERA 700 surgical microscope that now features integrated data injection for the very first time. This enables toric intraocular lenses to be aligned even more conveniently and precisely as the target axis is visible when looking into the microscope. Available options now include a space-saving ceiling mount and many different options and accessories.The modular platform of CALLISTO eye, which is now available in a new version, offers numerous assistance functions for cataract surgery, e.g. Z ALIGN for aligning toric intraocular lenses or the Rhexis Assistant for achieving the desired capsulorhexis size. Basic functions such as documentation and data import and workflow control are also offered.
In the field of refractive surgery Carl Zeiss is presenting the new ReLEx smile correction technique, in which femtosecond technology and precise lenticle extraction are combined into one minimally invasive correction technique for the first time – all in a single system: the VisuMax® from Carl Zeiss. Unlike LASIK, in which tissue is ablated with an excimer laser after opening a flap, the ReLEx smile method generates a refractive lenticle in the intact cornea, which is then removed through a small, less-than-four-millimeter incision. This flapless refractive method enables doctors to operate precisely, minimally invasive and therefore gently. “The ReLEx smile minimally invasive treatment method is pioneering and has the potential to bring about a paradigm shift in refractive laser surgery,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.
ESCRS attendees can obtain information about Carl Zeiss Meditec’s entire product and solution offering at booth B314 at the Reed Messe Vienna and register for the ZEISS events during the ESCRS at www.meditec.zeiss.com/escrs.JENA – 12 August 2011
Medical technology company Carl Zeiss Meditec successfully continued on its growth course in the third quarter and achieved a significant increase in revenue compared with the same period of the previous year.
Contact:
Petra Rettenmaier
Director Corporate Communications
Carl Zeiss Meditec AG
Göschwitzer Strasse 51-52
07745 Jena
Germany
Phone: +49 3641 220-331
Fax: +49 3641 220-112
Email: [email protected]
Patrick Kofler
Director of Investor Relations
Carl Zeiss Meditec AG
Göschwitzer Strasse 51-52
07745 Jena
Germany
Phone: +49 3641 220-106
Fax: +49 3641 220-117
Email: [email protected]
Brief profile
Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world’s leading medical technology companies. The company supplies innovative technologies and application-oriented solutions which enable doctors to improve the quality of life of their patients. It offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. In the field of microsurgery the company provides innovative visualization solutions. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising future-oriented technologies such as intraoperative radiotherapy. The Company's around 2,200 employees generated revenues of about EUR 676 million in fiscal year 2009/10 (ended Sept. 30).
Carl Zeiss Meditec is headquartered in Jena, Germany. In addition to other subsidiaries in Germany, the company is represented by over 50 percent of its employees at sites in the USA, Japan, Spain and France. 35 percent of Carl Zeiss Meditec shares are in free float. The remaining 65% are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industry. Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. During fiscal year 2009/109 the group of companies generated revenues of around EUR 2.98 billion. From fiscal year 2010/11, eyeglass lens manufacturer Carl Zeiss Vision will be integrated as an autonomous business group (revenues of EUR 880 million in fiscal year 2009/10). The Carl Zeiss Group now has approximately 24,000 employees, including more than 10,000 in Germany. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation). For more information, please go to http://www.meditec.zeiss.de